by | Oct 16, 2022 | Publications
BMC Cancer. 2022 Oct 15;22(1):1065. doi: 10.1186/s12885-022-10003-w. ABSTRACT BACKGROUND: Activated mutations in NOTCH1 are drivers of T-cell type acute lymphoblastic leukemia/lymphoma. The γ-secretase inhibitor (GSI), which suppresses the function of NOTCH1, is...
by | Oct 15, 2022 | Publications
Indian J Med Microbiol. 2022 Oct 11:S0255-0857(22)00180-3. doi: 10.1016/j.ijmmb.2022.09.007. Online ahead of print. ABSTRACT PURPOSE: This study aimed to estimate herpes simplex virus type 2 (HSV-2) seroprevalence and its association with HIV, HBV, HCV, HTLV-1&2...
by HTLV | Oct 12, 2022 | Publications
Front Public Health. 2022 Sep 8;10:963790. doi: 10.3389/fpubh.2022.963790. eCollection 2022. ABSTRACT Hemophilia is a recessive genetic disease caused by a mutation on the X chromosome that has been linked to a high risk of transfusion-transmitted infections,...
by HTLV | Oct 12, 2022 | Publications
Clin Lymphoma Myeloma Leuk. 2022 Oct;22 Suppl 2:S397. doi: 10.1016/S2152-2650(22)01573-7. ABSTRACT CONTEXT: Adult T-cell leukemia/lymphoma (ATLL) is a rare, human T-cell lymphotropic virus 1 (HTLV-1)-driven malignancy with treatment challenges and a dismal prognosis....
by HTLV | Oct 12, 2022 | Publications
J Med Virol. 2022 Sep 26. doi: 10.1002/jmv.28176. Online ahead of print. ABSTRACT Hydrogen sulfide (H2 S) is a redox gasotransmitter. It has been shown that H2 S has a key role in host antiviral defense by inhibiting interleukin production and S-sulfhydrating Keap1...
by HTLV | Oct 12, 2022 | Publications
Front Immunol. 2022 Sep 8;13:953650. doi: 10.3389/fimmu.2022.953650. eCollection 2022. ABSTRACT HTLV-1 is a global infection with 5-20 million infected individuals. Although only a minority of infected individuals develop myelopathy, lymphoproliferative malignancy, or...
